Immune Training Backfires: β-Glucan Worsens Inflammatory Bone Loss in Mice
New research reveals that β-glucan immune training unexpectedly increases bone-destroying osteoclasts, worsening arthritis and periodontitis.
Summary
Researchers discovered that β-glucan, a compound known to boost immune memory, has an unexpected dark side. While it strengthens immunity against infections and cancer, it also trains bone-destroying cells called osteoclasts to become more aggressive. In mouse studies, animals pre-treated with β-glucan developed worse arthritis and gum disease, with increased bone loss and inflammation. The effect worked through a process called trained immunity, where immune cells develop enhanced responses to future challenges. This finding is particularly important because β-glucan is being tested in cancer treatments, but could potentially worsen bone-related side effects of immunotherapy.
Detailed Summary
This groundbreaking study reveals a concerning side effect of immune training that could impact millions of patients. Trained immunity, where immune cells develop enhanced memory responses, has shown promise in fighting infections and cancer. However, this research demonstrates that the same process can backfire when it comes to bone health.
The researchers used β-glucan, a fungal compound that induces trained immunity, to pre-treat mice before exposing them to inflammatory conditions. They tested three different models: ligature-induced periodontitis (gum disease), collagen-antibody-induced arthritis, and serum transfer arthritis. In all cases, mice that received β-glucan training developed significantly worse disease outcomes.
The mechanism involves osteoclasts, specialized cells that break down bone tissue. β-glucan training caused bone marrow precursors and circulating monocytes to become more prone to developing into osteoclasts. When inflammation struck, these trained cells produced more bone-destroying osteoclasts and inflammatory molecules like IL-17, TNF, and IL-1β. The researchers identified MITF (melanogenesis-associated transcription factor) as a key player in this process.
The clinical implications are significant. β-glucan preparations are currently being tested in cancer immunotherapy trials, often combined with checkpoint inhibitors. Since inflammatory bone loss is already a known side effect of cancer immunotherapies, this research suggests that β-glucan could potentially worsen these complications. The findings also help explain why inflammatory bone diseases like arthritis and periodontitis often occur together – trained immunity may create a systemic predisposition to bone loss.
However, this doesn't negate β-glucan's benefits entirely. The research highlights the need for careful risk-benefit analysis and potentially developing strategies to harness immune training's anti-cancer effects while minimizing bone-related complications.
Key Findings
- β-glucan immune training increased bone loss in three mouse models of inflammatory disease
- Trained monocytes showed enhanced ability to differentiate into bone-destroying osteoclasts
- MITF transcription factor emerged as key mediator of trained osteoclastogenesis
- Effect required secondary inflammatory challenge, consistent with trained immunity principles
- Adoptive transfer of trained monocytes worsened arthritis in recipient mice
Methodology
Researchers used three mouse models (ligature-induced periodontitis, collagen-antibody-induced arthritis, and K/BxN serum transfer arthritis) with β-glucan pre-treatment 7 days before disease induction. They employed flow cytometry, gene expression analysis, histological assessment, and adoptive transfer experiments to characterize mechanisms.
Study Limitations
Study conducted only in mouse models; human relevance needs confirmation. Long-term effects of β-glucan training on bone health remain unclear. The research focused on inflammatory bone loss models and may not apply to other bone conditions.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.